Management of Abdominal Post-surgical Scar With Ozoaqua Versus Standard Care

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorLaboratorios Ozoaqua

About this trial

A prospective, randomized clinical study with a blinded evaluator to compare a post-surgical abdominal scar care protocol using Ozoaqua products versus standard care in patients undergoing open abdominal surgery. The primary objective is to assess whether the use of Ozoaqua, initiated in the immediate postoperative period according to wound evolution, improves abdominal scar quality at 3 months compared with usual care.

The proposed design is an initial single-center study at the Clínica Universidad de Navarra, with 1:1 random allocation to two parallel arms: an intervention group receiving standard care plus Ozoaqua ozonated soap and oil, and a control group receiving standard care only. The primary scar assessment will be performed by a blinded evaluator, while treatment will be open-label due to the nature of the topical intervention.

The target population consists of adult patients undergoing scheduled open abdominal surgery, with primary wound closure and an assessable linear abdominal scar. Follow-up will be integrated into routine clinical care, including an in-hospital phase during the first postoperative days and outpatient visits at approximately 2 weeks, 1 month and 3 months, with the latter being the main study visit.

The primary endpoint will be scar quality at 3 months, assessed using the POSAS scale, particularly the blinded observer score. Secondary endpoints will include the patient POSAS score, scar evolution, wound complications, pain, pruritus, satisfaction, cutaneous adverse events, rescue treatments and adherence.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥18 years

Scheduled open abdominal surgery

Primary wound closure

Assessable linear abdominal scar

Disqualifiers

Known allergy to treatment components

Active infection or significant dehiscence in the immediate postoperative period

Planned use of specific scar treatments -silicone products, laser therapy, local corticosteroids- except as clinical rescue treatment

Inability to complete follow-up

Trial design

Design model

Parallel

Treatments tested in this trial

  • Ozonated product-based protocol for scar hygiene and care

    Other intervention

    Ozonated oil soap and ozonated oil, added to standard postoperative care

Treatment groups

144 Participants
are divided into 2 treatment groups
Group A: Ozoaqua protocol treament + standard postoperative careExperimental treatment 1 intervention
Group B: Standard postoperative careNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Observer score on the POSAS scale at 3 months, using the linear version for surgical scars

The POSAS (Patient and Observer Scar Assessment Scale) is a validated scale used to assess scar quality from two complementary perspectives: that of the clinical observer and that of the patient. Only the clinical observer component of the POSAS scale will be assessed. This assessment will be performed by a blinded evaluator, who will be unaware of the patients' allocation to the treatment groups. The observer component of the POSAS scale, in its linear version for surgical scars, allows the quality of linear scars to be assessed through the clinical evaluation of parameters such as: * Vascularization * Pigmentation * Thickness * Relief * Pliability * Surface area Each parameter is scored from 1 to 10, where 1 corresponds to normal skin and 10 to the worst imaginable scar condition for that domain. The total observer score is obtained by summing the six items, resulting in a range of 6 to 60 points; lower scores indicate better scar quality.

Time frame
3 months

Secondary outcomes

1

Patient score on the POSAS scale at 3 months

The POSAS (Patient and Observer Scar Assessment Scale) is a validated scale used to assess scar quality from two complementary perspectives: that of the clinical observer and that of the patient. Only the patient component of the POSAS scale will be assessed. This assessment will be completed by the patient, reflecting her own perception of the scar and associated symptoms. The patient component of the POSAS scale, allows scar quality to be assessed from the patient's perspective through the evaluation of parameters such as: Pain Pruritus Color Stiffness Thickness Irregularity Each parameter is scored from 1 to 10, where 1 corresponds to normal skin or absence of symptoms and 10 to the worst imaginable scar condition or symptom intensity for that domain. The total patient score is obtained by summing the six items, resulting in a range of 6 to 60 points; lower scores indicate better perceived scar quality.

Time frame
3 months
2

Observer score on the POSAS scale at 1 month

Time frame
1 month
3

Patient score on the POSAS scale at 1 month

Time frame
1 month
4

Surgical wound complications within the first month after the intervention

Surgical wound complications within the first 30 postoperative days, defined as the occurrence of any local event related to the abdominal incision, including infection, partial or complete dehiscence, seroma, hematoma, persistent exudate, or the need for additional wound care procedures/interventions.

Time frame
1 month

Other outcomes

1

Adverse events during the follow-up period

Any adverse event will be recorded, defined as any unfavourable medical occurrence or clinically relevant change in the patient's health status, regardless of its possible relationship with the study product/intervention. In addition, any relevant modification to concomitant medical treatments during the follow-up period will be documented.

Time frame
3 months
2

Treatment-related cutaneous adverse events during the follow-up period

The occurrence of any undesirable cutaneous event in the application area or perilesional area during the treatment and follow-up period will be recorded, regardless of its causal relationship with the products used. These events may include irritation, erythema, stinging, burning sensation, pruritus, dryness, contact dermatitis, local allergic reaction, desquamation, local pain, or any other clinically relevant cutaneous reaction.

Time frame
3 months
3

Treatment adherence

Treatment adherence will be assessed at each visit through a directed interview with the patient, in which they will be asked whether the topical product has been applied according to the regimen specified in the protocol. Any missed applications, temporary interruptions, incorrect application, or relevant deviations in product use will be recorded.

Time frame
3 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: